Galapagos (GLPG) Q1 2025 earnings summary

Executive summary

• Announced the planned separation into two publicly traded entities, with leadership changes including Henry Gosebruch as SpinCo CEO and Dr. Paul Stoffels' retirement, focusing on value creation through streamlined operations and targeted strategies.

• Progressed transformation into a focused cell therapy company, advancing clinical pipeline, decentralized manufacturing, and global partnerships.

• Dosed first U.S. patient in Atalanta-1 study for GLPG5101, completed enrollment in key cohorts, and selected MCL as lead indication for pivotal trial targeting approval in 2028.

• Expanded operations and manufacturing capabilities in China, Europe, and the U.S. to accelerate cell therapy development.

• Deprioritized GLPG5201 to focus resources on flagship GLPG5101 program.

Financial highlights

• Q1 2025 net revenues were €75.0 million, up 20% year-over-year, with €13.8 million from supply and €61.2 million from collaborations.

• Operating loss increased to €158.7 million from €33.1 million, mainly due to €111 million in restructuring and separation costs.

• Net loss for Q1 2025 was €153.4 million, compared to a net profit of €90.2 million in Q1 2024.

• Cash and financial investments totaled €3.3 billion at March 31, 2025; operational cash burn for Q1 2025 was €37.1 million.

• R&D expenses rose 155% year-over-year to €182.7 million, reflecting increased investment in oncology and clinical trials.

Outlook and guidance

• Normalized annual cash burn guidance (excluding restructuring) is €175–225 million post-separation.

• Galapagos expects to retain approximately €500 million in cash post-separation, funding operations and pipeline through 2028.

• SpinCo to be established by mid-2025, subject to shareholder and regulatory approvals, and capitalized with €2.45 billion.

• Top-line data from indolent NHL cohort expected in Q2 2025; new MCL data in H2 2025; at least one next-gen candidate to enter clinic by year-end.

• First patients to be dosed with armed bispecific CAR T candidate in 2025.